Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery
Key Takeaways
- Nootropic peptides like Selank and Semax are short amino-acid chains studied for anxiety and depression. They lack FDA approval and have limited human evidence from small Russian trials.
- Selank shows some anxiolytic effects in published studies, with roughly 40% of patients responding within 1–3 days.1 Semax has more data for cognitive support and secondary antidepressant effects through BDNF upregulation.1
- Neither peptide has been replicated in large Western randomized controlled trials, and long-term safety data beyond a few months are unavailable.
- The primary safety concern involves sourcing peptides from unregulated vendors. Medically supervised protocols with lab monitoring and personalized dosing help reduce risk.
- Mirror Plastic Surgery offers physician-led peptide therapy under the direct care of Dr. Akash Chandawarkar, with every protocol tailored to the client’s labs and goals.
Discuss Whether Peptide Therapy Is Right For You
Why Mirror Plastic Surgery Leads With Physician Expertise
Dr. Akash Chandawarkar, MD, is the founder of Mirror Plastic Surgery and the lead physician for peptide therapies. He studied neuroscience and nuclear engineering at MIT before graduating with Honors from Harvard Medical School through the Harvard-MIT Division of Health Sciences and Technology. He completed a seven-year integrated plastic and reconstructive surgery residency at Johns Hopkins University and a Stanford University Biodesign Innovation Fellowship. He is board certified by the American Board of Plastic Surgery.
Dr. Chandawarkar combines neuroscience training with hands-on clinical experience in his peptide practice. Every protocol is designed around each client’s labs and physiology. He often advises clients to delay or skip treatments that do not match their needs, prioritizing long-term results over short-term revenue.
At Mirror Plastic Surgery, peptide therapies stay under Dr. Chandawarkar’s direct supervision. His neuroscience background allows him to explain clearly what nootropic peptides for anxiety and depression can realistically offer. Clients receive personalized, medically supervised care from consultation through follow-up.
Meet With Dr. Chandawarkar About Peptide Therapy
Key Concepts And Terminology For Nootropic Peptides
Nootropic peptides are short chains of amino acids that act on brain pathways involved in mood, stress response, and cognition. Two peptides drive most of the research and clinical interest in this space:
- Selank: A synthetic seven-amino-acid peptide derived from tuftsin, an endogenous immunomodulatory peptide. It is studied primarily for anxiety and is proposed to modulate GABA and serotonin pathways.
- Semax: A synthetic seven-amino-acid peptide derived from ACTH(4-7). It is studied primarily for cognitive support and neuroprotection, with proposed effects on BDNF and neuroplasticity.
The mechanisms most discussed in the literature include:
- GABA: The brain’s primary inhibitory neurotransmitter. Selank is proposed to modulate GABA-A receptors indirectly and does not bind the benzodiazepine site directly.
- Serotonin: A neurotransmitter involved in mood regulation. Both Selank and Semax may influence serotonin turnover through distinct pathways.
- BDNF (Brain-Derived Neurotrophic Factor): A protein that supports neuron growth and synaptic plasticity. Semax is proposed to upregulate BDNF via melanocortin receptor signaling.
- Neuroplasticity: The brain’s ability to reorganize and form new neural connections. BDNF is a key mediator of this process.
Several features distinguish nootropic peptides from standard psychiatric treatments:
- Mechanism: SSRIs and SNRIs work by blocking serotonin and norepinephrine reuptake, while benzodiazepines bind directly to GABA-A receptors. Nootropic peptides are proposed to act differently. Rather than blocking a receptor or transporter, they may modulate these systems indirectly through gene expression, neurotransmitter turnover, and neurotrophic signaling.
- Onset: Benzodiazepines typically take effect within roughly 15–30 minutes. SSRIs take 4–6 weeks. Selank is reported to produce anxiolytic effects within 1–3 days in some studies. Semax effects on mood may take 7–14 days.
- Dependency Profile: Benzodiazepines carry risks of tolerance, dependence, and withdrawal. Published Selank trials report no dependence or withdrawal, although long-term data are lacking.
- Regulatory Status: No nootropic peptide is FDA-approved for anxiety, depression, or any psychiatric condition.
Selank For Anxiety: What The Evidence Shows
Selank is the nootropic peptide most studied for anxiety. Its proposed mechanism involves modulation of GABA and serotonin pathways. Many descriptions compare its target pathways to benzodiazepines while emphasizing a different dependency profile.
Evidence Grade: Human Data Exists But Is Limited.
The human evidence for Selank comes primarily from small Russian clinical trials. The largest published trial, by Zozulya et al. (2008), enrolled 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank to the benzodiazepine medazepam. Results suggested anxiolytic effects comparable to medazepam, with additional antiasthenic effects and fewer side effects such as sedation and memory impairment.1 A 2014 trial by Medvedev et al. in 60 patients with phobic-anxiety and somatoform disorders reported anxiolytic and mild nootropic effects, with the anxiolytic effect persisting approximately one week after the last dose.1
These studies were small, conducted at single Russian sites, and have not been independently replicated in Western trials. No Western peer-reviewed randomized controlled trial for Selank in anxiety disorders is registered on ClinicalTrials.gov or indexed in PubMed as of 2026. No Phase 3 trials using modern CONSORT-compliant methodology have been published.
Available data address several practical questions:
- How Fast Does Selank Kick In? Approximately 40% of patients in the 2008 trial were rapid responders whose Hamilton Anxiety scores dropped within the first 1–3 days.1 The remaining 60% showed gradual improvement reaching significance by day 14.
- How Long Can It Be Taken? Published trials ran 14–28 days. Only one human study states a treatment duration of 14 days, and long-term safety data beyond a few months do not exist.
- Does It Cause Weight Gain? No published trial reports weight gain as a side effect of Selank.
- Does It Affect Cortisol? A 2011 secondary analysis found that after 10 days of intranasal Selank, serum cortisol dropped by 22% versus baseline.
- Can It Be Taken At Bedtime? Some users report mild drowsiness. Evening dosing may be preferred for those sensitive to sedation, and timing should be discussed with a physician.
Selank functions as an investigational option that belongs within established psychiatric care, not as a stand-alone replacement. A physician should supervise any trial.
Semax For Depression: What The Evidence Shows
Semax is the nootropic peptide most studied for cognitive support and neuroprotection, with proposed antidepressant effects. Its mechanism involves upregulation of BDNF and neuroplasticity, a pathway shared with some antidepressants.
Evidence Grade: Human Data Exists But Is Limited; Some Evidence Is Preclinical Only.
The most rigorous published human study of Semax enrolled 110 post-stroke patients and reported improved functional outcomes. However, the trial was non-randomized, non-placebo-controlled, and conducted by a single Russian research group. A 2013 randomized controlled trial in 58 patients with mild to moderate depression reported a mean reduction of 8.2 points on the Hamilton Depression Rating Scale versus 3.1 points for placebo, with a 32% increase in serum BDNF in the Semax group.1 This study has not been replicated in Western trials.
Preclinical studies show Semax reverses stress-induced anhedonia and restores hippocampal BDNF in rodent models.1 These findings are promising but do not establish clinical efficacy in humans.
Comparing Selank And Semax For Mood Symptoms
The two peptides are sometimes discussed together, yet their evidence bases and proposed uses differ. Selank has more direct human data for anxiety. Semax has more human data for cognitive and neurological outcomes, with antidepressant effects appearing as secondary findings. Neither has been tested head-to-head for depression in a controlled trial.
Review The Evidence With Dr. Chandawarkar
Evidence Grading: Where The Research Stands
Evidence strength and regulatory status vary widely across peptides. Understanding those differences helps set realistic expectations before considering treatment. The table below links each peptide to its claimed use, the level of human evidence, and its regulatory position. No peptide in this table has strong human evidence for anxiety or depression, and none is FDA-approved for psychiatric use.
| Peptide | Claimed Use | Human Evidence Status | Key Regulatory Note |
|---|---|---|---|
| Selank | Anxiety | Human data exists but limited; five human studies totaling 244 participants, nearly all conducted at Russian institutions | Not FDA-approved; listed under bulk drug substances nominated but withdrawn; no active compounding pathway |
| Semax | Depression, cognition | Human data exists but limited; mostly neurological populations; antidepressant effects are secondary findings | Not FDA-approved; FDA advisory panel voted 8–5 in July 2026 to recommend compounding list addition; vote is not binding |
| NAD+ | Energy, anti-aging | Insufficient evidence for anxiety or depression | Not FDA-approved for psychiatric use |
| DSIP | Sleep, mood | Preclinical only for mood; limited human sleep data; evidence characterized as outdated and inconclusive | Not FDA-approved |
| Dihexa | Cognition | Preclinical only | Not FDA-approved |
The uneven evidence in this table mirrors an uneven regulatory landscape. Understanding FDA classification helps clarify what is available through pharmacies and what remains experimental.
Safety, Regulation, And Sourcing
The FDA’s bulk drug substances list is the key regulatory reference for understanding the legal landscape of nootropic peptides in the United States.
Selank acetate (TP-7) appears on the FDA’s page for bulk drug substances nominated but withdrawn, which means the nomination process ended procedurally and Selank does not have an active FDA compounding pathway. The FDA has stated that compounded drugs containing Selank acetate may pose immunogenicity risk for certain routes of administration due to the potential for aggregation and peptide-related impurities. The agency also lacks important information about safety issues raised by Selank acetate administered to humans.
Semax was reviewed by the FDA’s Pharmacy Compounding Advisory Committee in July 2026. The panel voted 8–5 to recommend adding Semax to the compounding list, but the vote is not binding, and the FDA will ultimately decide. FDA staff had proposed not adding Semax to the 503A Bulks List, citing missing characterization data and insufficient evidence for the nominated indications.
Why obtaining peptides from unregulated sources is the primary risk:
- No third-party testing for purity or identity
- Unknown concentration and potential contamination
- No medical supervision or dosing guidance
- No lot recall path if problems arise
These gaps explain why coverage of peptides in mental health emphasizes supply chain risk. The main concern centers on how peptides are sourced and monitored rather than on a specific molecule alone.
Mirror Plastic Surgery sources peptides from reputable providers with batch testing and medical oversight. Every protocol is designed around each client’s labs and physiology.
Ask About Supervised Peptide Sourcing
How Nootropic Peptides Fit Into A Supervised Care Plan
A medically supervised nootropic peptide protocol for anxiety and depression at Mirror Plastic Surgery follows a structured approach:
- Consultation: An in-depth review of your medical history, current medications, symptoms, and treatment goals. This consultation typically lasts 30–60 minutes.
- Lab Panels: Where appropriate, lab work is ordered to identify root causes and rule out contraindications. This may include thyroid function, hormone panels, and inflammatory markers.
- Peptide Selection: Based on your labs, history, and goals, Dr. Chandawarkar selects the most appropriate peptide or peptide combination. Selank is commonly discussed for anxiety, and Semax for depression and cognitive support.
- Dosing Oversight: Dosing is individualized. This guide does not list specific doses because dosing depends on your unique physiology and response.
- Monitoring: Follow-up appointments assess efficacy, tolerability, and any needed adjustments.
- Tapering And Maintenance: If you and your physician decide to stop, a tapering plan is developed. Effects typically diminish when peptides are stopped, similar to stopping any health regimen, rather than producing pharmacological withdrawal.
Plan A Personalized Peptide Protocol
Supervised Use: Interactions, Duration, And Stopping
Can You Take Selank With Antidepressants? No published human studies have tested Selank with SSRIs, SNRIs, or other antidepressants. The absence of documented interactions reflects an absence of studies rather than an absence of risk. Mechanistically, the pathways are largely distinct, but interactions and pre-existing conditions require physician review. Combining without medical supervision is not advisable.
How Long Can You Take Selank? Almost every published Selank study runs between 2 and 6 weeks. Long-term, multi-month or multi-year human safety data are lacking. A physician can help determine an appropriate duration based on your response and goals.
What Happens When You Stop? Stopping Semax or Selank after weeks of daily use does not produce withdrawal tremors or rebound anxiety in the published literature. Users may notice a return to baseline, which reflects the absence of an effect rather than a pharmacological withdrawal. A tapering plan can be developed with your physician.
Mirror Plastic Surgery’s concierge model includes direct access to Dr. Akash Chandawarkar via text or scheduled telemedicine appointments, providing consistent support throughout your journey.
Common Misconceptions About Nootropic Peptides
Misconception: Nootropic Peptides Are A Proven Replacement For Antidepressants Or Benzodiazepines. No peptide is FDA-approved for anxiety or depression, and current evidence does not support replacing FDA-approved psychiatric medications with peptide therapy.
Misconception: Buying Peptides Online Is Equivalent To Medically Supervised Therapy. Analyses of online peptide markets show contamination and mislabeled concentrations are common. Online peptides lack third-party testing, medical oversight, and dosing guidance.
Misconception: All Peptides Work The Same Way Or Produce The Same Results In Everyone. Peptides have different mechanisms, evidence bases, and regulatory statuses. Results vary based on genetics, physiology, and protocol. A personalized approach with lab work helps account for these differences.
Misconception: Peptides Are Only For Weight Loss. Peptides are studied for inflammation, recovery, cognitive support, anxiety, and more. Weight loss represents one application among many.
The questions below build on these misconceptions and focus on practical decisions about use, combinations, and expectations.
Frequently Asked Questions
How Fast Does Selank Kick In, And How Long Can You Take It?
The onset of Selank’s anxiolytic effects varies between individuals. As noted in the evidence section, roughly 40% of patients in the largest trial responded within 1–3 days, while the rest improved more gradually over two weeks. Published human trials have run for 14–28 days, and long-term safety data beyond a few months do not exist in the peer-reviewed literature. A physician can help determine an appropriate duration based on your individual response, goals, and medical history.
Can You Take Selank With Antidepressants Or Benzodiazepines?
No published human studies have specifically tested Selank in combination with SSRIs, SNRIs, MAOIs, or benzodiazepines. The absence of documented interactions reflects a gap in research rather than confirmed safety. Mechanistically, Selank’s proposed GABAergic and enkephalinase pathways are largely distinct from SSRI reuptake blockade, but the systems interact, and individual variation matters. Anyone currently taking psychiatric medications should disclose all medications to their physician before considering Selank. Combining without medical supervision is not advisable and may carry uncharacterized risks.
Is Selank Or Semax Better For Depression?
Selank and Semax have different evidence bases and proposed mechanisms. Selank has more direct human data for anxiety, with antidepressant effects appearing as secondary observations in some trials. Semax has more human data for cognitive and neurological outcomes, particularly in post-stroke populations, with antidepressant effects also appearing as secondary findings. Neither has been tested head-to-head for depression in a controlled trial. The choice between them, or the decision to avoid them, depends on your specific symptom profile, labs, and medical history, and should be made with a physician.
Does Selank Cause Weight Gain, And Does It Affect Cortisol?
No published clinical trial reports weight gain as a side effect of Selank. The 22% cortisol reduction mentioned earlier has not been replicated in a larger, independently conducted trial, so it should be interpreted cautiously. If cortisol regulation is a concern, especially with adrenal or HPA axis issues, discuss this with your physician before starting any peptide protocol.
What Happens When You Stop Taking Nootropic Peptides?
The published literature does not document a pharmacological withdrawal syndrome for Selank or Semax. When either peptide is stopped, its effects on mood, cognition, and anxiety typically diminish as the peptide clears and downstream signaling returns to baseline. This pattern reflects the end of an ongoing effect rather than a rebound or withdrawal. Some users describe a return to their pre-treatment baseline, which can feel like a decline if they had adapted to the peptide’s effects. A structured tapering plan developed with your physician can help you evaluate benefits and decide whether a maintenance protocol makes sense.
Conclusion: A Clear View Of Peptides For Anxiety And Depression
Nootropic peptides like Selank and Semax remain promising yet unproven options for anxiety and depression. The human evidence is limited and largely comes from Eastern European studies that have not been independently replicated in Western trials. No peptide is currently FDA-approved specifically for the treatment of anxiety or depression, and most peptide research for these conditions remains early-stage.
The central safety concern involves unregulated sourcing without medical supervision. A safer path uses a medically supervised trial with lab work, personalized dosing, and a clear tapering plan. Nootropic peptides should complement established psychiatric care rather than replace it.
If you want to explore whether nootropic peptides for anxiety and depression may be appropriate for you, schedule a consultation with Dr. Akash Chandawarkar at Mirror Plastic Surgery. Every protocol is built around your labs, your history, and your goals, with medical oversight that supports both safety and meaningful results.
Disclaimer: Results from peptide therapies vary significantly from person to person. Many peptides are not FDA-regulated. The information in this article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment.
Schedule Your Peptide Consultation
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
